Skip to main content


First-Line Ibrutinib Effective for CLL/SLL Irrespective of Cytogenetic or Mutational Risk Features

December 10, 2020


Jan Burger, MD, PhD, Department of Leukemia, MD Anderson Cancer Center, Houston, Texas, discusses an analysis of the RESONATE-2 and iLLUMINATE studies, which explored outcomes of first-line ibrutinib in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and high-risk genomic features.

These results were presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting.

Listen to the original podcast on Oncology Learning Network.

Back to Top